SCHEMBL7530776

SCHEMBL7530776

CCCCC(CC)CON

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.57
ALDH1A1 P00352 7/20 0.56
TDP1 Q9NUW8 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.55
TSHR P16473 4/20 0.50
ATM Q13315 1/20 0.50
CA2 P00918 3/20 0.43
RECQL P46063 1/20 0.41
ADRB2 P07550 1/20 0.40
ADRB1 P08588 1/20 0.40
ADRB3 P13945 1/20 0.40
LMNA P02545 2/20 0.39
MMP9 P14780 1/20 0.39
MMP8 P22894 1/20 0.39
MMP14 P50281 1/20 0.39
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CHRM2 P08172 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyclopropane SCHEMBL8660451 0.94 CYP3A4 (0.52) CYP3A4ALDH1A1TDP1L3MBTL1TSHR
SCHEMBL23308783 0.84 LMNA (0.48) CYP3A4ALDH1A1TDP1L3MBTL1TSHR
SCHEMBL25964137 0.81 LMNA (0.50) CYP3A4ALDH1A1TDP1TSHRADRB2
SCHEMBL80432 0.80 CYP3A4 (0.67) CYP3A4ALDH1A1TDP1L3MBTL1TSHR
SCHEMBL5198521 0.80 CYP3A4 (0.59) CYP3A4ALDH1A1TDP1L3MBTL1TSHR
SCHEMBL1715469 0.79
Barium SCHEMBL10790747 0.78 CYP3A4 (0.64) CYP3A4ALDH1A1TDP1L3MBTL1TSHR
Calcium SCHEMBL10786160 0.78 CYP3A4 (0.64) CYP3A4ALDH1A1TDP1L3MBTL1TSHR
SCHEMBL23087841 0.78 CYP3A4 (0.64) CYP3A4ALDH1A1TDP1L3MBTL1TSHR
Potassium SCHEMBL18260591 0.78 CYP3A4 (0.64) CYP3A4ALDH1A1TDP1L3MBTL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016068341-A1 THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION 富士フイルム株式会社 2016-05-06 WO disclosed
CN-102378810-B Detergent composition and cleaning method using the same MATSUMOTO YUSHI SEIYAKU KK 2013-07-31 CN disclosed
CN-102378810-A Detergent composition and cleaning method using the same MATSUMOTO YUSHI SEIYAKU KK 2012-03-14 CN disclosed
US-6376712-B2 REDUCTION OF THE CORRESPONDING OXIME COMPOUND CENTRAL GLASS COMPANY, LIMITED (JP) 2002-04-23 US disclosed
US-20020013500-A1 Process for producing trifluoromethylbenzylamines CENTRAL GLASS COMPANY, LIMITED (JP) 2002-01-31 US disclosed
US-6331649-B1 REDUCING AN OXIME BY CATALYTIC HYDROGENTATION IN SOLVENT CONTAINING AN ACID CENTRAL GLASS COMPANY, LIMITED (JP) 2001-12-18 US disclosed
CN-1047614-C Aqueous functional fluid having improved resistance to micro-organisms CINCINNATI MILACRON INC (US) 1999-12-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013500-A1 Process for producing trifluoromethylbenzylamines MAOB, CYP2F1, AGL CYP3A4 204/4885ALDH1A1 622/4885TDP1 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.